Debjani Singh: Channeling a river of data for clean energy, sustainability
Kathy McCarthy, associate laboratory director for Fusion and Fission Energy and Science at the Department of Energy’s Oak Ridge National Laboratory, has been elected fellow of the American Nuclear Society for her nationally and internationally recognized leadership in nuclear energy and fusion.
An ORNL-led team comprising researchers from multiple DOE national laboratories is using artificial intelligence and computational screening techniques – in combination with experimental validation – to identify and design five promising drug therapy approaches to target the SARS-CoV-2 virus.
Scientists at Oak Ridge National Laboratory have developed a solvent that results in a more environmentally friendly process to recover valuable materials from used lithium-ion batteries, supports a stable domestic supply chain for new batteries
The Department of Energy’s Office of Science has selected five Oak Ridge National Laboratory scientists for Early Career Research Program awards.
Belinda Akpa is a chemical engineer with a talent for tackling big challenges and fostering inclusivity and diversity in the next generation of scientists.
Rich Giannone uses bioanalytical mass spectrometry to examine proteins, the primary driver in biological systems.
Scientists at Oak Ridge National Laboratory have devised a method to identify the unique chemical makeup of every lithium-ion battery around the world, information that could accelerate recycling, recover critical materials and resolve a growing waste stream.
The Accelerating Therapeutics for Opportunities in Medicine , or ATOM, consortium today announced the U.S. Department of Energy’s Oak Ridge, Argonne and Brookhaven national laboratories are joining the consortium to further develop ATOM’s artificial intelligence, or AI-driven, drug discovery platform.
A rare isotope in high demand for treating cancer is now more available to pharmaceutical companies developing and testing new drugs.
Scientists have found new, unexpected behaviors when SARS-CoV-2 – the virus that causes COVID-19 – encounters drugs known as inhibitors, which bind to certain components of the virus and block its ability to reproduce.